CME Group Inc (CME)vsWest Pharmaceutical Services Inc (WST)
CME
CME Group Inc
$281.25
-1.95%
FINANCIAL SERVICES · Cap: $101.91B
WST
West Pharmaceutical Services Inc
$325.92
+1.21%
HEALTHCARE · Cap: $22.08B
Smart Verdict
WallStSmart Research — data-driven comparison
CME Group Inc generates 109% more annual revenue ($6.74B vs $3.22B). CME leads profitability with a 63.3% profit margin vs 16.9%. WST appears more attractively valued with a PEG of 2.89. WST earns a higher WallStSmart Score of 67/100 (B-).
CME
Buy65
out of 100
Grade: C+
WST
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CME.
Margin of Safety
-32.4%
Fair Value
$185.95
Current Price
$325.92
$139.97 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 63 of every $100 in revenue as profit
Strong operational efficiency at 69.8%
Large-cap with strong market position
Conservative balance sheet, low leverage
Earnings expanding 21.3% YoY
Generating 1.2B in free cash flow
Earnings expanding 56.1% YoY
Safe zone — low bankruptcy risk
Strong operational efficiency at 21.7%
Revenue surging 21.0% year-over-year
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : CME
The strongest argument for CME centers on Profit Margin, Operating Margin, Market Cap. Profitability is solid with margins at 63.3% and operating margin at 69.8%. Revenue growth of 14.4% demonstrates continued momentum.
Bull Case : WST
The strongest argument for WST centers on EPS Growth, Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.9% and operating margin at 21.7%. Revenue growth of 21.0% demonstrates continued momentum.
Bear Case : CME
The primary concerns for CME are Piotroski F-Score, PEG Ratio.
Bear Case : WST
The primary concerns for WST are PEG Ratio, P/E Ratio. A P/E of 41.8x leaves little room for execution misses.
Key Dynamics to Monitor
CME profiles as a mature stock while WST is a growth play — different risk/reward profiles.
WST carries more volatility with a beta of 1.17 — expect wider price swings.
WST is growing revenue faster at 21.0% — sustainability is the question.
CME generates stronger free cash flow (1.2B), providing more financial flexibility.
Bottom Line
WST scores higher overall (67/100 vs 65/100), backed by strong 16.9% margins and 21.0% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CME Group Inc
FINANCIAL SERVICES · FINANCIAL DATA & STOCK EXCHANGES · USA
CME Group Inc. (Chicago Mercantile Exchange, Chicago Board of Trade, New York Mercantile Exchange, The Commodity Exchange) is an American global markets company. It is the world's largest financial derivatives exchange, and trades in asset classes that include agricultural products, currencies, energy, interest rates, metals, stock indexes and cryptocurrencies futures.
Visit Website →West Pharmaceutical Services Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.
Compare with Other FINANCIAL DATA & STOCK EXCHANGES Stocks
Want to dig deeper into these stocks?